Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer

Abstract

<br/><b>Objective</b>: To investigate short- and long-term treatment effects and side reactions of lobaplatin plus 5-Fucombined and concurrent radiotherapy in treating patients with inoperable middle-advanced stage esophagealcancer. <br/><b>Methods</b>: Sixty patients with middle-advanced stage esophageal squamous cell cancer were retrospectivelyanalyzed. All patients were administered lobaplatin (50 mg intravenously) for 2 h on day 1, and 5-Fu (500 mg/m2)injected intravenously from day 1 to 5 for 1 cycle, in an interval of 21 days for totally 4 cycles. At the same time,late-course accelerated hyperfractionated three-dimensional conformal radiotherapy was performed. Patientswere firstly treated with conventional fractionated irradiation (1.8 Gy/d, 5 times/week, a total of 23 treatments,and DT41.4 Gy), and then treated with accelerated hyperfractionated irradiation (1.5 Gy, 2 times/d, a totalof 27 Gy in 9 days, an entire course of 6-7 weeks, and DT 68.4Gy). <br/><b>Results</b>: All patients completed treatment,including 10 complete response (CR), 41 partial response (PR), 7 stable disease (SD), and 2 progressive disease(PD). The total effective rate was 85.0% (51/60). Thirty-nine patients had an increased KPS score. One-, 2-, and3-year survival rates were 85.3%, 57.5%, and 41.7%, respectively. The median survival time was 27 months.The adverse reactions included myelosuppression, which was mainly degreeⅠ and Ⅱ. The occurrence rate ofradiation esophagitis was 17.5%. No significant hepatic or renal toxicity was observed. <br/><b>Conclusion</b>: Lobaplatinplus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advancedstage esophageal cancer. However, this result warrants further evaluation by randomized clinical studies.